Nanoformulation of D-α-tocopheryl Polyethylene Glycol 1000 Succinate-B-poly(ε-caprolactone-ran-glycolide) Diblock Copolymer for Breast Cancer Therapy.

Laiqiang Huang,Hongbo Chen,Yi Zheng,Xiaosong Song,Ranyi Liu,Kexin Liu,Xiaowei Zeng,Lin Mei
DOI: https://doi.org/10.1039/c1ib00026h
2011-01-01
Integrative Biology
Abstract:The purpose of this research was to develop formulation of docetaxel-loaded biodegradable TPGS-b-(PCL-ran-PGA) nanoparticles for breast cancer chemotherapy. A novel diblock copolymer, D-alpha-tocopheryl polyethylene glycol 1000 succinate-b-poly(epsilon-caprolactone-ran-glycolide) [TPGS-b-(PCL-ran-PGA)], was synthesized from epsilon-caprolactone, glycolide and D-alpha-tocopheryl polyethylene glycol 1000 succinate by ring-opening polymerization using stannous octoate as catalyst. The obtained copolymers were characterized by (1)H NMR, GPC and TGA. The docetaxel-loaded TPGS-b-(PCL-ran-PGA) nanoparticles were prepared and characterized. The data showed that the fluorescence TPGS-b-(PCL-ran-PGA) nanoparticles could be internalized by MCF-7 cells. The TPGS-b-(PCL-ran-PGA) nanoparticles achieved significantly higher level of cytotoxicity than commercial Taxotere (R). MCF-7 xenograft tumor model on SCID mice showed that docetaxel formulated in the TPGS-b-(PCL-ran-PGA) nanoparticles could effectively inhibit the growth of tumor over a longer period of time than Taxotere (R) at the same dose. In conclusion, the TPGS-b-(PCL-ran-PGA) copolymer could be acted as a novel and potential biologically active polymeric material for nanoformulation in breast cancer chemotherapy.
What problem does this paper attempt to address?